 Psychedelics-based neuroscience company Enveric Biosciences NASDAQ: ENVB announced the development of EV104a and EV104b, new molecular conjugates for Osteoarthritis and other pain indications. EV104a and EV104b are specifically designed to optimize pharmacokinetics and therapeutic synergy via improved delivery, targeting abilities, and potency to potentially be more efficacious and display fewer side effects than current treatments. 